Immutep (ASX:IMM) - Share price, News & Analysis

IMM fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	5/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

IMM Stock Overview

Immutep Limited, a biotechnology company, engages in the research and development of pharmaceutical product candidates.

Rewards

Trading at 97.9% below our estimate of its fair value

Earnings are forecast to grow 75.92% per year

Risk Analysis

Shareholders have been diluted in the past year

Does not have meaningful revenue (A$4M)

Immutep Competitors

Aroa Biosurgery

ASX:ARX

AU$287.9m

Mesoblast

ASX:MSB

AU$633.7m

Opthea

ASX:OPT

AU$475.1m

Actinogen Medical

ASX:ACW

AU$127.5m

Price History & Performance

Summary of all time highs, changes and price drops for Immutep
Historical stock prices
Current Share Price	AU$0.39
52 Week High	AU$0.72
52 Week Low	AU$0.30
Beta	1.69
1 Month Change	20.00%
3 Month Change	20.00%
1 Year Change	-41.79%
3 Year Change	39.29%
5 Year Change	25.81%
Change since IPO	-87.00%

Recent News & Updates

May 19

Is Immutep (ASX:IMM) Weighed On By Its Debt Load?

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...

Shareholder Returns

	IMM	AU Biotechs	AU Market
7D	-2.5%	0.5%	-1.2%
1Y	-41.8%	-8.0%	-0.009%

Return vs Industry: IMM underperformed the Australian Biotechs industry which returned -8% over the past year.

Return vs Market: IMM underperformed the Australian Market which returned -0% over the past year.

Price Volatility

Is IMM's price volatile compared to industry and market?
IMM volatility
IMM Average Weekly Movement	8.9%
Biotechs Industry Average Movement	9.9%
Market Average Movement	9.3%
10% most volatile stocks in AU Market	16.3%
10% least volatile stocks in AU Market	4.2%

Stable Share Price: IMM is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: IMM's weekly volatility (9%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1987	n/a	Marc Voigt	https://www.immutep.com

Immutep Limited, a biotechnology company, engages in the research and development of pharmaceutical product candidates. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its lead product candidate is eftilagimod alpha (efti or IMP321), a recombinant protein that is in Phase IIb clinical trial as a chemoimmunotherapy combination for metastatic breast cancer.

Immutep Fundamentals Summary

How do Immutep's earnings and revenue compare to its market cap?
IMM fundamental statistics
Market Cap	AU$328.84m
Earnings (TTM)	-AU$26.33m
Revenue (TTM)	AU$3.73m

89.2x

P/S Ratio

-12.7x

P/E Ratio

Is IMM overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
IMM income statement (TTM)
Revenue	AU$3.73m
Cost of Revenue	AU$22.39m
Gross Profit	-AU$18.66m
Other Expenses	AU$7.67m
Earnings	-AU$26.33m

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

n/a

Earnings per share (EPS)	-0.031
Gross Margin	-499.91%
Net Profit Margin	-705.34%
Debt/Equity Ratio	2.5%

How did IMM perform over the long term?

See historical performance and comparison

New valuation analysis is now available for all ASX stocks. This is in beta.

Future Growth

How is Immutep forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?

Future Growth Score

5/6

Future Growth Score 5/6

Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE

75.9%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings vs Savings Rate: IMM is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.8%).

Earnings vs Market: IMM is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: IMM's is expected to become profitable in the next 3 years.

Revenue vs Market: IMM's revenue (86.6% per year) is forecast to grow faster than the Australian market (4.8% per year).

High Growth Revenue: IMM's revenue (86.6% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: IMM is forecast to be unprofitable in 3 years.

Past Performance

How has Immutep performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE

-23.3%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: IMM is currently unprofitable.

Growing Profit Margin: IMM is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: IMM is unprofitable, and losses have increased over the past 5 years at a rate of 23.3% per year.

Accelerating Growth: Unable to compare IMM's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: IMM is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (7.7%).

Return on Equity

High ROE: IMM has a negative Return on Equity (-24.18%), as it is currently unprofitable.

Financial Health

How is Immutep's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: IMM's short term assets (A$107.7M) exceed its short term liabilities (A$7.9M).

Long Term Liabilities: IMM's short term assets (A$107.7M) exceed its long term liabilities (A$3.5M).

Debt to Equity History and Analysis

Debt Level: IMM has more cash than its total debt.

Reducing Debt: IMM's debt to equity ratio has reduced from 17.3% to 2.5% over the past 5 years.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: IMM has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: IMM has sufficient cash runway for 3 years if free cash flow continues to reduce at historical rates of 14.1% each year.

Dividend

What is Immutep current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate IMM's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate IMM's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if IMM's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if IMM's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as IMM has not reported any payouts.

Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

6.5yrs

Average management tenure

CEO

Marc Voigt (48 yo)

9.5yrs

Tenure

AU$994,587

Compensation

Mr. Marc Voigt has been the Chief Executive Officer of Immutep Limited (formerly, Prima BioMed Ltd) since July 9, 2014. Mr. Voigt has been an Executive Director of Immutep Limited since July 9, 2014. He se...

CEO Compensation Analysis

Compensation vs Market: Marc's total compensation ($USD703.09K) is about average for companies of similar size in the Australian market ($USD568.55K).

Compensation vs Earnings: Marc's compensation has increased whilst the company is unprofitable.

Leadership Team

Experienced Management: IMM's management team is seasoned and experienced (6.5 years average tenure).

Board Members

Experienced Board: IMM's board of directors are considered experienced (4.9 years average tenure).

Ownership

Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 22.7%.

Data	Last Updated (UTC time)
Company Analysis	2022/05/25 00:00
End of Day Share Price	2022/05/25 00:00
Earnings	2021/12/31
Annual Earnings	2021/06/30